{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:22:35Z","timestamp":1790508155965,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004888","name":"University Hospital Center of Quebec-Laval University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015115","name":"Fondation de l\u2019Universit\u00e9 Laval","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015115","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Soci\u00e9t\u00e9 canadienne du cancer","doi-asserted-by":"publisher","award":["704970"],"award-info":[{"award-number":["704970"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.radonc.2025.111124","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:50:10Z","timestamp":1757375410000},"page":"111124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087)"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-1233","authenticated-orcid":false,"given":"G.","family":"Morton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vigneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-6125","authenticated-orcid":false,"given":"M.","family":"Barkati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Helou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-2901","authenticated-orcid":false,"given":"J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-0886","authenticated-orcid":false,"given":"C.L.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Delouya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-9208","authenticated-orcid":false,"given":"C.","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4214-9148","authenticated-orcid":false,"given":"A.G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Batchelar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-0497","authenticated-orcid":false,"given":"M.D.","family":"Brundage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Parulekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111124_b0005","unstructured":"NCCN Guidelines Version 1.2025 Prostate Cancer. https:\/\/www.nccn.org. Accessed March 24 2025."},{"key":"10.1016\/j.radonc.2025.111124_b0010","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.brachy.2021.07.006","article-title":"Low dose rate brachytherapy for primary treatment of localized prostate cancer: a systemic review and executive summary of an evidence-based consensus statement","volume":"20","author":"King","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111124_b0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.brachy.2020.10.009","article-title":"HDR brachytherapy as monotherapy for prostate cancer: a systematic review with meta-analysis","volume":"20","author":"Viani","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111124_b0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111124_b0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijrobp.2013.10.016","article-title":"Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models","volume":"88","author":"Mavroidis","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111124_b0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111124_b0035","article-title":"Highly favorable preliminary clinical and toxicity outcomes for low-and intermediate-risk prostate cancer patients treated with high-dose-rate brachytherapy in a single fraction of 19 Gy","volume":"93(3)","author":"Krauss","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111124_b0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111124_b0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111124_b0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2025.111124_b0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijrobp.2013.10.010","article-title":"Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival","volume":"88","author":"Lo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111124_b0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2015.02.023","article-title":"High dose-rate brachytherapy boost for intermediate risk prostate cancer: long-term outcomes of two different treatment schedules and early biochemical predictors of success","volume":"115","author":"Helou","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111124_b0070","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clon.2021.11.004","article-title":"Four-year prostate-specific antigen response rate as a predictive measure in intermediate-risk prostate cancer treated with ablative therapies: the SPRAT analysis","volume":"34","author":"Glicksman","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.111124_b0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111124_b0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clon.2021.11.009","article-title":"Defining biochemical cure after low dose rate prostate brachytherapy: external validation of 4-year prostate-specific antigen nadir as a predictor of 10- and 15-year disease-free survival","volume":"34","author":"Noble","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2025.111124_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.brachy.2021.05.010","article-title":"PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: a phase 2 randomized pilot study","author":"Reynaud","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2025.111124_b0090","doi-asserted-by":"crossref","unstructured":"Hudson JM, Loblaw A, McGuffin M, Chung HT, Tseng CL, Helou J et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy: A 9-year update. Radiother Oncol 2024;198:110381.10.1016\/j.radonc.2024.110381.","DOI":"10.1016\/j.radonc.2024.110381"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025046286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025046286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:19:29Z","timestamp":1780114769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025046286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":17,"alternative-id":["S0167814025046286"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111124","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111124"}}